Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p087 | (1) | ICCBH2017

Cranial synostosis and Chiari 1 malformation in X-linked hypophosphatemic rickets

Rothenbuhler Anya , Bacchetta Justine , Debza Yahya , Lambert Anne-Sophie , Merzoug Valerie , Linglart Agnes , Adamsbaum Catherine , Di Rocco Federico

Background: X-linked hypophosphatemic rickets (XLHR) represents the most common form of hypophosphatemia.Aim: The aim of this prospective study was to describe and analyze the incidence of cranial and cervico-occipital junction (COJ) anomalies in a series of children with XLHR.Patients and methods: Seventeen children (13 girls, 4 boys, mean age 7.3 years) followed for XLHR at the French national reference center for rare diseases o...

ba0003pp185 | Chondrocytes and cartilage | ECTS2014

Disturbed cartilages of the mandible in achondroplasia are associated with defective mandible shape and position

Duplan Martin Biosse , Di Rocco Federico , Heuze Yann , Gaudas Emilie , Komla-Ebri Davide , Kaci Nabil , Benoist-Lasselin Catherine , Legeai-Mallet Laurence

FGFR3 activating mutations are responsible for achondroplasia (ACH), the most common form of dwarfism. ACH clinical features include short stature, midface hypoplasia, frontal bossing and prognathism and both endochondral and membranous ossifications are disturbed. It is unknown if abnormal mandibles are present in ACH. To date, it is believed that primary (Meckel’s) and secondary (angular and condylar) cartilages play important roles in determining the final shape and po...

ba0007p51 | (1) | ICCBH2019

Higher dose of burosumab is needed for treatment of children with severe forms of X-linked hypophosphatemia

Zhukouskaya Volha V , Audrain Christelle , Lambert Anne-Sophie , Colao Annamaria , Kamenicky Peter , Adamsbaum Catherine , Nevoux Jerome , Chaussain Catherine , Wicart Philippe , Briot Karine , Di Rocco Federico , Trabado Severine , Prie Dominique , Rothenbuhler Anya , Linglart Agnes

Background and aim: Burosumab is a monoclonal antibody against anti-FGF23, which has been recently approved for treatment of X-linked hypophosphatemia (XLH). Beyond clinical trials, little is known about its efficacy/safety in clinical practice which is the aim of study.Patients/Methods: 39 children with XLH were switched from conventional therapy to burosumab (starting dose 0.4 mg/kg), because of following indications: non-responder to conventional ther...